Monte Rosa announces 2025 milestones and $377M cash position funding into 2028

Monte Rosa Therapeutics, Inc.

Preliminary cash, equivalents, and securities of $377.0M as of Dec 31, 2024; funds operations into 2028.
Initial Phase 1 SAD/MAD data for VAV1 degrader MRT-6160 expected Q1 2025; Novartis license deal gave $150M upfront.
Updated biomarker and activity data from MRT-2359 Phase 1/2 in MYC-driven solid tumors expected Q1 2025.
IND filing for NEK7 degrader MRT-8102 in H1 2025; CDK2 candidate nomination in H1 2025.
Second-generation NEK7 candidate with CNS penetration nomination in H2 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.